The scale of the worldwide pharmaceutical manufacturing industry was estimated at USD 405.52 billion in 2020 and is projected to increase at a compound annual growth rate (CAGR) of 11.34 percent from 2021 to 2028. With the introduction of new technology and more efficient, less expensive manufacturing methods, the pharmaceutical industry has experienced a significant transition. Additionally, the growing demand has significantly benefited by rising investment flows in this area. Between 2021 to 2027, the pharmaceuticals manufacturing sector in Southeast Asia will expand by 13 percent yearly, reaching a market value of $29.1 billion. High research and development spending, a modernizing industrial base, and an overarching rise in the prevalence of chronic diseases in the area are all contributing to this surge.
One of the leading pharmaceutical companies, RV Group has a unique position where the company’s strong R&D and manufacturing base with dominant front-end presence in the Southeast and CIS regions has made it amongst the leading players. The success story of RV Group, which started in 2006 with one person and now a team of 3500+ people is a unique story.In a short span RV has become one of the leading pharmaceutical companies in ASEAN region with in-depth expertise and a deep understanding on the wants and needs of the ASEAN region.
Vision and Mission
RV’s vision is to be the finest provider of world class quality healthcare products at affordable prices. This vision is supported by its core values which is deeply ingrained in every team member that are focused, fast, flexible, and forward looking. RV stands for ”Real Value to life through science” and is committed to provide Real Value to all stake holders – Customer, Business partner, Shareholder and Employees.
RV group plans to maintain its dominant position in ASEAN with continued focus on therapeutic area of Gastrointestinal disease including Liver health, Oncology and Cardio diabetics. Company shall further strengthen its presence in OTC with brands like AMEFLU, STAR, TYDOL, Gloskin, Dizzo, Fefozinc, B Complete, and more. At the same time company’s Strong R&D and Back end which has been built over years will help company to enter Europe and USA.
While the vision and mission of the company keeps the operations in the right direction, the success of RV Group can be attributed to its seasoned management staff, which is constantly honing its skills. The leadership of RV Group has amassed more than a century of experience in the pharmaceutical sector across several nations, including R&D, manufacturing, strategy, business development, commerce, distribution, and finance.
Services and Products
RV Group’s journey started in 2006 when the founder, Rajiv Kumar Sharma established RV Life Sciences in Hong Kong. A year later the company set up its first official representative offices in Cambodia, Myanmar, and Vietnam. As a strategy the company focused on the ASEAN region, addressing the needs of the market in this region. In a short span of 2 years, the company was able to innovate and come up with its own line of OTC products and launch of which was facilitated through one of the company’s subsidiaries, known popularly as RV Healthcare UK. In the following two years, the firm focused its efforts on establishing Reliv Pharma (DMCS) within Vietnam in addition to establishing RV Healthcare in Singapore.
All through this duration, the company was also simultaneously building a strong backend and R&D structure to promote and improve its range of products.
In the next few years, RV expanded even more, entering the CIS markets through their partner company APC in 2011. This expansion was mainly focused on the countries of Uzbekistan, Tajikistan, and Kazakhstan. RV group entered in India by acquisition of manufacturing unit - RVLL (previously Atra) which has been major contract manufacturing company for leading global companies like Servier, Merck and P&G. Also, RV group acquired a front-end sales and marketing company – Winston with a small sales team of 100 Medical reps.
“In the ASEAN region, RV Group is a one-stop shop for manufacturing and retail with branch offices in Vietnam, Philippines, Myanmar and Cambodia. RV group has a wellknown household name – OPV Pharma (now RV-OPV) and in process of upgradation of it manufacturing unit to EUGMP and TGA so that Company can start exporting products to Europe and Australia. RV group is amongst top 7 pharma companies in Myanmar with the largest pharmaceutical manufacturing unit, located across 146 hectares, it has 9 assembly lines including large volume parenterals and small volume parenterals.
Further in INDIA, RV group has RVLL India which is an EU-GMP approved manufacturing facility with lines to make oral medications including tablets and capsules with total capacity of 3 billion units. RVLL has a strong R&D center and thus company has built up a healthy range for unique and differentiated products to launch in Europe, Russia, Mexico. RVLL India is in the process of building up USFDA approvable manufacturing unit to fulfill companies’ ambition to get in USA market.
Within the ASEAN region, RV Group is a leading company due to its dominant front-end presence, experienced and seasoned sales and marketing workforce, and equally powerful back-end infrastructure, including its R&D unit in India, which offers technical and development support for all markets in ASEAN and CIS nations, as well as its cutting-edge production facilities in India, Vietnam, and Myanmar.
Given the nature of the sector, international market trends, significant success criteria, and core competencies of RV Group, the company’s growth has been driven by aggressive mergers, competitive acquisitions, and strategic collaborations in the industry. Some of the partners including World leading Pharma partners like VIATRIS (MYLAN), LUPIN, GLENMARK, CIPLA, NATCO, MSN, RELIANCE stand as the testament to RV Group’s standing in the industry. Progressing forward, companies strong back and R&D center will help company create differentiated product portfolios using modern pharmaceutical technologies, making it possible to create products that are difficult to replicate.
RV Group is a leading company due to its dominant front-end presence, experienced and seasoned sales and marketing workforce, and equally powerful back-end infrastructure, including its R&D unit in India
The company is always working relentlessly to expand its OTC line of products in the area and introduce specialized oncology medicines (including biosimilars, hepatitis drugs, cardio diabetics, and other categories). Its strategy to increase access to the necessary HIV and hepatitis B and C medications have become a success factor for the RV Group. The medications provided by RV Group in Vietnam are used to treat 80 percent of HIV patients and 70 percent of Hepatitis B and C patients. The ability to provide such a huge population with access to life-saving medications is an outstanding accomplishment.
Future Roadmap
With these missions in mind, and a continuous effort to keep manufacturing better products to address the unmet needs of the patient, RV Group is investing heavily in research and development to formulate new products, with such unique features that cannot be easily replicated by the competition.“
RV group shall be getting into European and Australian market though its world class manufacturing units and expects its first registration in Europe by middle of 2023. Entry in Australia is being planned through tie ups and Acquisitions. BY the year 2024, RV group will have products in USA which happens to be the largest pharma market.
RV group already has a dominant presence in Southeast Asia and rightly poised for major leap in the coming year to be a significant player in Europe and USA.
.jpg "Technology in Cancer Care: A story of evolving paradigms")
.jpg "Bringing Shop Floor to Manufacturer's palm: Smart Factory Solutions for tomorrow")
